Orrick is advising PHW-Group in its sale of Lohmann SE (Lohmann Animal Health) to Elanco, the animal health division of Eli Lilly and Company. The PHW Group produces and markets high-quality poultry specialities including animal feed and animal health, human nutrition and human healthcare products. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives, selling its products in over 80 countries around the world. The transaction follows a comprehensive bidding process.
According to a press release issued by Eli Lilly, “The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.”
Under the terms of the agreement, Lilly will acquire all assets of Lohmann SE and its subsidiaries, including Lohmann Animal Health. These assets include a range of vaccines and feed additives, commercial capabilities, and manufacturing sites in Cuxhaven, Germany and Winslow, Maine. No other terms of the transaction were disclosed. The transaction is expected to close in the second quarter of 2014, contingent upon clearance from regulatory authorities and other customary closing conditions.
The Orrick team was led by Munich partner Jörg Ritter and Düsseldorf partner Stefan Weinheimer, and includes corporate associates Thomas Strassner, Christopher Mayston, Claudia Hölzl and Lara Finken and partners Peter Rooney in New York and Harry Clark in Washington, D.C. The antitrust & competition team was led by partners Douglas Lahnborg in London and Brussels and Till Steinvorth in Düsseldorf supported by associates Matthew Rose and Enzo Marasà, as well as antitrust & competition partners Garret Rasmussen and Tony Kim in Washington, D.C. supported by of counsel Pat Zeigler and associate David Smith. Real estate was handled by Düsseldorf partner Annette Pospich and associate Christoph Wenderoth as well as New York of counsel Ralph Stone.